Apriem Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Apriem Advisors's REGN Position: Q3 2026 in Review
Apriem Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 6.2% in Q3 2026, selling an estimated $20.4K and leaving 407 shares worth $309K. The position accounts for 0.03% of the portfolio, ranked #151.
Apriem Advisors first reported a position in REGN in Q1 2015 and has held it in 29 quarters since. The position peaked at $22.6M in Q4 2022. 1,433 funds tracked by Wall St. Rank hold REGN as of Q3 2026.
- Apriem Advisors held 407 shares of Regeneron Pharmaceuticals worth $309K as of Q3 2026.
- Apriem Advisors sold 27 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $20.4K.
- Regeneron Pharmaceuticals made up 0.03% of Apriem Advisors's portfolio in Q3 2026, its #151 holding.
- Apriem Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 29 quarters since.
- Apriem Advisors's Regeneron Pharmaceuticals position peaked at $22.6M in Q4 2022.
- 1,433 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.
Based on Apriem Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.